Concor® Bioequivalence Study in Chinese Participants (Darmstadt-Nantong)

Inclusion Criteria: * Participants are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests and cardiac monitoring * Participant must have a body weight within 50-90 kilogram (kg) and body mass index (BMI) within the range 19-26 kilogram per meter square (kg/m2) (inclusive) * Participant must have negative screen for alcohol and drugs of abuse at screening and on admission * Both male and female participants. The Investigator confirms that each participant agrees to use appropriate contraception and barriers, if applicable * Participant must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF * Other protocol defined inclusion criteria could apply Exclusion Criteria: * Participant must not have any condition, including any uncontrolled disease state, that in the Investigator's opinion constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation * Participant should not have positive screen for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, human immunodeficiency virus (HIV) antibodies, and treponema pallidum antibodies * Participant must not have received any prescription or non-prescription medication within 28 days before the first study intervention administration, including multivitamins and herbal products (example, St John's Wort, or traditional Chinese medicines) * Participant must not have participation in a study trial within 90 days prior to first drug administration; Blood donation (equal or more than 400 milliliter \[mL\]) or significant blood loss within 90 days prior to first drug administration * Other protocol defined exclusion criteria could apply